CN113820494A - Blood polypeptide group new coronary biomarker - Google Patents
Blood polypeptide group new coronary biomarker Download PDFInfo
- Publication number
- CN113820494A CN113820494A CN202110814967.3A CN202110814967A CN113820494A CN 113820494 A CN113820494 A CN 113820494A CN 202110814967 A CN202110814967 A CN 202110814967A CN 113820494 A CN113820494 A CN 113820494A
- Authority
- CN
- China
- Prior art keywords
- patients
- biomarker
- new coronary
- apelin
- polypeptide group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 22
- 210000004369 blood Anatomy 0.000 title claims abstract description 14
- 239000008280 blood Substances 0.000 title claims abstract description 14
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 12
- 102000003896 Myeloperoxidases Human genes 0.000 claims abstract description 23
- 108090000235 Myeloperoxidases Proteins 0.000 claims abstract description 23
- 102000018746 Apelin Human genes 0.000 claims abstract description 20
- 108010052412 Apelin Proteins 0.000 claims abstract description 20
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 claims abstract description 20
- 108010056852 Myostatin Proteins 0.000 claims description 2
- 102000004472 Myostatin Human genes 0.000 claims 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract description 17
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 abstract description 16
- 208000025721 COVID-19 Diseases 0.000 abstract description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 12
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 11
- 101150004578 gdf-8 gene Proteins 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 230000022379 skeletal muscle tissue development Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 2
- 230000002503 metabolic effect Effects 0.000 description 13
- 238000011084 recovery Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 230000004110 gluconeogenesis Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004116 glycogenolysis Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108091008803 APLNR Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102100030949 Apelin receptor Human genes 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000010120 metabolic dysregulation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5757—Vasoactive intestinal peptide [VIP] or related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Abstract
The invention relates to the technical field of biomarkers, and particularly relates to a blood polypeptide group new coronary biomarker which comprises Myeloperoxidase (MPO), Apelin and myogenesis inhibitory protein (GDF 8). The MPO, Apelin and GDF8 are all simple noninvasive blood polypeptide group biomarkers, and the blood polypeptide group biomarkers can be used for quickly and effectively detecting the new insulin resistance of a new coronary patient so as to prevent and treat patients with COVID-19 according to symptoms.
Description
Technical Field
The invention relates to the technical field of biomarkers, in particular to a blood polypeptide group new coronary biomarker.
Background
Many new coronary patients with metabolic diseases such as diabetes, obesity, hypertension and cardiovascular diseases have very poor prognosis. The literature reports that the mortality rate of new coronary patients suffering from diabetes and hypertension is very high, and the mortality rate of patients suffering from cardiovascular diseases is as high as 10.5%. In addition, patients with type 2 diabetes mellitus who have COVID-19 have impaired glycemic control and require high doses of insulin. Therefore, metabolic complications such as cardiovascular diseases may worsen new coronary conditions and clinical outcomes. In patients with COVID-19, metabolic dysregulation without metabolic-related underlying disease will continue until recovery. Thus, it can be concluded that there is a potential association between COVID-19 and metabolism. SARS-CoV-2 can directly enter and attack metabolic tissues and organs through angiotensin converting enzyme 2(ACE2) as a receptor. Since ACE2 is abundantly expressed not only in the upper respiratory system but also in the heart, endothelial cells, renal tubular epithelial cells, intestinal epithelial cells and pancreas, attack of the pancreas by viruses causes insufficient insulin secretion to cause acute pancreatitis. However, only a few cases report metabolic deterioration in patients without metabolic-related underlying diseases, such as hyperglycemia, in which the proportion of patients increases from 11.9% to 28.4% at the time of admission. Furthermore, there is no direct evidence that the new coronavirus induces type 1 diabetes, and especially that COVID-19 causes insulin resistance, resulting in hyperglycemia. However, clinical studies and related mechanistic studies are lacking. We found, through a retrospective clinical study, elevated blood glucose and insulin resistance in new coronary patients without metabolic underlying disease. Therefore, it is particularly critical to explore the relationship of COVID-19 to the glycolipid metabolism of patients and their mechanisms, and to find biomarkers that may worsen the metabolic system of patients after recovery of the new coronary disease.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a blood polypeptide group new coronary biomarker.
The purpose of the invention is realized by the following technical scheme:
a blood polypeptide group new coronary biomarker comprises Myeloperoxidase (MPO), Apelin and myogenesis inhibitory protein (GDF 8).
MPO is a heme-containing enzyme that reacts with hydrogen peroxide to produce hypochlorite and other halide oxidizing agents. Released by neutrophils during infection, it can bind to chromatin and other proteins to form Neutrophil Extracellular Traps (NETs). NET has been reported to be involved in the formation of immunothrombi in COVID-19 severe patients and was observed in coronary thrombi in patients with COVID-19 myocardial infarction. We found that MPO is significantly upregulated not only in critically ill patients, but also in non-critically ill patients. Thus, elevated MPO may have a broad impact on COVID-19 complications. In vitro studies show that MPO can induce hepatic gluconeogenesis, and therefore, MPO can be used as a biomarker for new insulin resistance of patients with new coronary disease.
Apelin is an endogenous ligand of the G protein-coupled receptor APJ, which is reported to have a down-regulating effect on the production of Angiotensin Converting Enzyme (ACE) and angiotensin ii (ang ii) and to be beneficial to various systems including metabolism. The down-regulation of ACE2 following SARS-CoV-2 infection may disrupt the balance of ACE with ACE2, thereby further inhibiting degradation of Ang II. Therefore, we conclude that Apelin may be of potential benefit to patients with CoVID-19 dysbolism. We found that Apelin is down-regulated during the infection phase and remains low during the convalescent phase, and in vitro studies indicate that Apelin inhibits gluconeogenesis, glycogenolysis and lipogenesis. Therefore, Apelin can be used as a biomarker for new insulin resistance of new coronary patients.
GDF8 was originally found to be a regulatory factor for muscle mass, and recent studies have shown that GDF8 deficient mice exhibit reduced insulin resistance, and elevated GDF8 promotes insulin resistance. Although myostatin was observed to be negatively associated with HOMA-IR and blood glucose in our study, we believe this is a compensatory mechanism. We found that GDF8 is down-regulated during the infection phase and remains low during the recovery phase, and in vitro studies indicate that GDF8 can inhibit gluconeogenesis, glycogenolysis and lipogenesis. Therefore, GDF8 can be used as a biomarker for new onset of insulin resistance in patients with new coronary artery disease.
Compared with the prior art, the invention has the following technical effects:
the MPO, Apelin and GDF8 are simple and noninvasive blood polypeptide group biomarkers, and the blood polypeptide group biomarkers can be used for quickly and effectively detecting the new insulin resistance of a new coronary patient so as to prevent and treat patients with COVID-19 according to symptoms.
Drawings
FIG. 1 is a schematic diagram showing the detection of HOMA-IR in serum of a patient with new coronary artery disease;
FIG. 2 is a schematic diagram showing the detection of the neocoronary metabolic disorder biomarker MPO in serum of a neocoronary patient;
FIG. 3 is a schematic diagram of detection of Apelin, a new crown metabolic disorder biomarker in serum of a new crown patient;
FIG. 4 is a schematic diagram of detection of new coronary metabolic disorder biomarker GDF8 in serum of new coronary patients;
FIG. 5 is a graph showing the correlation analysis results between the metabolism factors MPO, Apelin, GDF8 and HOMA-IR.
Detailed Description
The following further describes the embodiments of the present invention. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
The test methods used in the following experimental examples are all conventional methods unless otherwise specified; the materials, reagents and the like used are, unless otherwise specified, commercially available reagents and materials.
Example 1
A blood polypeptide group new coronary biomarker comprises Myeloperoxidase (MPO), Apelin and myogenesis inhibitory protein (GDF 8).
Experimental example 1
Collecting the serum of 10 healthy people, 34 patients without metabolic basic disease infection stage and 34 patients without metabolic basic disease recovery stage, respectively detecting the insulin content by using a Luminex kit, and calculating the HOMA-IR value; the result is shown in figure 1, HOMA-IR in serum of new coronary patients is still abnormal continuously in the recovery period and can not return to a normal state, which proves that the metabolic abnormality of organisms is caused by new coronavirus infection. The result shows that the new coronavirus causes the insulin resistance of the body of a patient, the A picture is HOMA-IR, compared with a healthy control group, the HOMA-IR value in the infection period is increased, the recovery period is still in a high-level state, and the recovery period cannot be recovered to a normal state. P < 0.05.
Experimental example two
Serum of 10 healthy people, 29 patients without metabolic basic disease in non-severe infection stage, 29 patients without metabolic basic disease in non-severe recovery stage, 5 patients without metabolic basic disease in severe infection stage and 5 patients without metabolic basic disease in recovery stage is collected, and the Luminex kit is used for respectively detecting the content of MPO, Apelin and GDF 8. MPO (fig. 2), Apelin (fig. 3) and GDF8 (fig. 4) in serum of new coronary patients were significantly elevated or down-regulated during non-critical and critical infectious phases and failed to return to normal levels regardless of non-critical and critical recovery phases. The results show that the MPO content of the new crown infected patients is still in an elevated state in the recovery period, and Apelin and GDF8 are still maintained at a low level and can not be recovered to a normal state. P < 0.05; p < 0.01.
Experimental example III
According to clinical data, correlation analysis of MPO, Apelin and GDF8 with HOMA-IR is carried out, and the results are shown in FIG. 5, which shows that MPO, Apelin and GDF8 have good correlation with changes of HOMA-IR. MPO, Apelin and GDF8 have good correlation with HOMA-IR, and further prove that MPO, Apelin and GDF8 can be used as a biomarker of new onset insulin resistance caused by new crowns.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the present invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (1)
1. A blood polypeptide group new coronary biomarker is characterized by comprising myeloperoxidase, Apelin and myostatin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110814967.3A CN113820494A (en) | 2021-07-19 | 2021-07-19 | Blood polypeptide group new coronary biomarker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110814967.3A CN113820494A (en) | 2021-07-19 | 2021-07-19 | Blood polypeptide group new coronary biomarker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113820494A true CN113820494A (en) | 2021-12-21 |
Family
ID=78912695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110814967.3A Pending CN113820494A (en) | 2021-07-19 | 2021-07-19 | Blood polypeptide group new coronary biomarker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113820494A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111879943A (en) * | 2020-07-10 | 2020-11-03 | 中山大学附属第五医院 | Application of SLAMF7 recombinant protein in preparation of medicine for treating neocoronary pneumonia |
| CN112526143A (en) * | 2020-12-03 | 2021-03-19 | 中山大学附属第五医院 | Application of myeloid cell trigger receptor 2 as novel coronavirus pneumonia diagnosis or treatment target |
| CN113092780A (en) * | 2021-03-31 | 2021-07-09 | 武汉大学中南医院 | Marker for identifying neocoronary pneumonia and application thereof |
-
2021
- 2021-07-19 CN CN202110814967.3A patent/CN113820494A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111879943A (en) * | 2020-07-10 | 2020-11-03 | 中山大学附属第五医院 | Application of SLAMF7 recombinant protein in preparation of medicine for treating neocoronary pneumonia |
| CN112526143A (en) * | 2020-12-03 | 2021-03-19 | 中山大学附属第五医院 | Application of myeloid cell trigger receptor 2 as novel coronavirus pneumonia diagnosis or treatment target |
| CN113092780A (en) * | 2021-03-31 | 2021-07-09 | 武汉大学中南医院 | Marker for identifying neocoronary pneumonia and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 胡智祥: "《医院临床检验技术操作规范与实（化）验室管理全书》", 银声音像出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Razvi et al. | Thyroid hormones and cardiovascular function and diseases | |
| González-López et al. | Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths | |
| Jiang et al. | Role of gamma-glutamyltransferase in cardiovascular diseases | |
| Cao et al. | Myocardial injury and COVID-19: Serum hs-cTnI level in risk stratification and the prediction of 30-day fatality in COVID-19 patients with no prior cardiovascular disease | |
| Zhou et al. | The anti-microbial peptide LL-37/CRAMP levels are associated with acute heart failure and can attenuate cardiac dysfunction in multiple preclinical models of heart failure | |
| Zhang et al. | The Predictive Value of Potential Hematological Biomarkers in Acute Coronary Syndrome. | |
| Shen et al. | Acute kidney injury and in-hospital mortality after coronary artery bypass graft versus percutaneous coronary intervention: a nationwide study | |
| Chee et al. | Prevalence and predictors of left ventricular diastolic dysfunction in Malaysian patients with type 2 diabetes mellitus without prior known cardiovascular disease | |
| Kim et al. | The association between metabolic syndrome and heart failure in middle-aged male and female: Korean population-based study of 2 million individuals | |
| Wu et al. | Association between cystatin C and cardiac function and long-term prognosis in patients with chronic heart failure | |
| CN113820494A (en) | Blood polypeptide group new coronary biomarker | |
| Cheng et al. | Nighttime blood pressure decline as a predictor of renal injury in patients with hypertension: a population-based cohort study | |
| Shah | Teneligliptin in early diabetic kidney disease: an observation in Asian Indian patients with type 2 diabetes mellitus in real-life scenario | |
| RU2566212C1 (en) | Method for multifactor prediction of remote unfavourable outcomes in patients suffered acute coronary syndrome with persistent st-segment elevation | |
| Yun et al. | Decreased renal function is a risk factor for subclinical coronary atherosclerosis in Korean postmenopausal women | |
| Altuntas et al. | The relationship between gender and systemic immune–inflammation index in patients with new-onset essential hypertension | |
| Iseki | Predictors of diabetic end‐stage renal disease in Japan | |
| Fitzgibbons et al. | Usefulness of pancreatitis-associated protein, a novel biomarker, to predict severity of disease in ambulatory patients with heart failure | |
| Cibi et al. | Cardiac tissue factor regulates inflammation, hypertrophy, and heart failure in mouse model of type 1 diabetes | |
| Gubina et al. | Ghrelin levels and decreased kidney function in patients with early stages of chronic kidney disease against the background of obesity | |
| Yıldız et al. | Relationship between brain natriuretic peptide, microalbuminuria, and contrast-induced nephropathy in patients with acute coronary syndrome | |
| Du et al. | Impact of Hypocalcemia on the Prognosis of Patients with Acute Myocarditis | |
| Madavi et al. | Mean platelet volume as a predictor of clinical outcomes in patients of acute myocardial infarction | |
| Liu et al. | The predictive value of pre-operative N-terminal pro-B-type natriuretic peptide in the risk of acute kidney injury after non-cardiac surgery | |
| Singh et al. | Estimation of Blood Glucose, Blood Urea, Serum Creatinine and Serum Cholesterol in Coronary Artery Disease Patients in a Tertiary Care Hospital: A Case Control Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211221 |